There has been and continues to be a surge in biotech innovation. But a pertinent question arises: how frequently are older, now outdated technologies phased out? Precision’s Ross Maclean, Phil Cyr and Ray Roth discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.
Payers have long maintained that the high cost of biologics relative to small-molecule drugs is unsustainable and a threat to their business model. However, a new analysis shows that many plans aren’t yet sold on giving less expensive biosimilars better footing on formularies compared to reference products.
Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important demonstrating the value to payers and health technology appraisal (HTA) organizations. In a dynamic regulatory and market access landscape, balancing the requirements of regulators and the expectations of payors can be challenging since there is no one-size-fits-all approach.
Precision will be at this year’s CAR-TCR Summit August 29 – September 1, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of cell therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?
This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.
Cell and gene therapies have the potential to revolutionize treatment of a wide range of diseases. With six new therapies approved in 2022, including the first allogeneic T-cell therapy, and at least as many slated for approval this year, the sector is poised for rapid growth. This innovation comes with challenges, though, and many consider 2023 to be a seminal year for establishing a strong foothold for advanced therapies in mainstream medicine.
Sponsored by Precision ADVANCE, this Endpoints webinar convened leading advanced therapy experts to discuss the future of cell therapy development and delivery. This discussion was moderated by John Khoury: EVP (Project Farma), and included insights from Chris McDonald: Global Head of Tech Ops (Kite Pharma), Mark Frattini: CMO (Cellectis), Jason Foster: CEO & ED (Ori Biotech), and Phil Cyr: SVP (Precision Value & Health).
Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), kicked off the event with a briefing on the state of the cell and gene therapy development landscape. With 475 members worldwide, ARM focuses on convening the sector, providing data and analysis, engaging with stakeholders, and enabling the development of advanced therapies. One of their key initiatives is modernizing healthcare systems to enable access to these novel therapeutics. Highlights of this briefing are provided in this summary.
The first FDA approved mRNA product was decades in the making, following many iterations throughout history the first mRNA vaccine in the US was brought to life. This achievement delivered aid to patients and healthcare providers during the most critical public health crisis in recent years. Since then, researchers have been operating at incredible speeds to develop more novel mRNA treatment options for patients, across many indications.
In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and Chad Salisbury, Senior Vice President of Project Farma (PF), discuss the mRNA revolution and its impact on the future of disease prevention and treatment.
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
